Omnicell (NASDAQ:OMCL) Upgraded at Zacks Research

Zacks Research upgraded shares of Omnicell (NASDAQ:OMCL) from a strong sell rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports. Zacks Research also issued estimates for Omnicell’s Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.29 EPS and Q3 2027 earnings at $0.28 EPS.

OMCL has been the topic of several other reports. Benchmark raised their target price on Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Wall Street Zen cut Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings lowered shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, March 2nd. Piper Sandler reissued an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Finally, KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price for the company in a research note on Wednesday, January 7th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.50.

Omnicell Stock Performance

NASDAQ:OMCL opened at $35.10 on Tuesday. The firm’s fifty day simple moving average is $43.98 and its 200 day simple moving average is $38.42. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of 877.72, a PEG ratio of 1.34 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The company had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. As a group, equities research analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is owned by corporate insiders.

Institutional Trading of Omnicell

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after acquiring an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its position in shares of Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after purchasing an additional 4,866 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Omnicell by 201.5% in the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, Penserra Capital Management LLC lifted its position in shares of Omnicell by 264.2% during the second quarter. Penserra Capital Management LLC now owns 9,215 shares of the company’s stock worth $270,000 after purchasing an additional 6,685 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.